In patients with unresectable HCC, outcomes with atezolizumab plus bevacizumab are not improved by the addition of low-dose ipilimumab.

The combination of pembrolizumab and EVX-01, a personalized peptide-based neoantigen cancer vaccine, demonstrated activity in patients with advanced melanoma, according to phase 2 study results.

“What’s important is that the patients enrolled into this trial are clearly representative of real-world patients that we are treating in our clinics every day,” said Rebecca A. Dent, MD. The median ...